277 related articles for article (PubMed ID: 30844552)
1. Immunoglobulin replacement for secondary immunodeficiency after B-cell targeted therapies in autoimmune rheumatic disease: Systematic literature review.
Wijetilleka S; Mukhtyar C; Jayne D; Ala A; Bright P; Chinoy H; Harper L; Kazmi M; Kiani-Alikhan S; Li C; Misbah S; Oni L; Price-Kuehne F; Salama A; Workman S; Wrench D; Karim MY
Autoimmun Rev; 2019 May; 18(5):535-541. PubMed ID: 30844552
[TBL] [Abstract][Full Text] [Related]
2. Recommendations for the management of secondary hypogammaglobulinaemia due to B cell targeted therapies in autoimmune rheumatic diseases.
Wijetilleka S; Jayne DR; Mukhtyar C; Ala A; Bright PD; Chinoy H; Harper L; Kazmi MA; Kiani-Alikhan S; Li CK; Misbah SA; Oni L; Price-Kuehne FE; Salama AD; Workman S; Wrench D; Karim MY
Rheumatology (Oxford); 2019 May; 58(5):889-896. PubMed ID: 30590695
[TBL] [Abstract][Full Text] [Related]
3. Rituximab-associated Hypogammaglobulinemia in pediatric patients with autoimmune diseases.
Khojah AM; Miller ML; Klein-Gitelman MS; Curran ML; Hans V; Pachman LM; Fuleihan RL
Pediatr Rheumatol Online J; 2019 Aug; 17(1):61. PubMed ID: 31462263
[TBL] [Abstract][Full Text] [Related]
4. Immunoglobulin G replacement for the treatment of infective complications of rituximab-associated hypogammaglobulinemia in autoimmune disease: a case series.
Roberts DM; Jones RB; Smith RM; Alberici F; Kumaratne DS; Burns S; Jayne DR
J Autoimmun; 2015 Feb; 57():24-9. PubMed ID: 25586449
[TBL] [Abstract][Full Text] [Related]
5. Rituximab-associated hypogammaglobulinemia in autoimmune rheumatic diseases: a single-center retrospective cohort study.
Wade SD; Kyttaris VC
Rheumatol Int; 2021 Jun; 41(6):1115-1124. PubMed ID: 33811499
[TBL] [Abstract][Full Text] [Related]
6. Rituximab-associated hypogammaglobulinemia: incidence, predictors and outcomes in patients with multi-system autoimmune disease.
Roberts DM; Jones RB; Smith RM; Alberici F; Kumaratne DS; Burns S; Jayne DR
J Autoimmun; 2015 Feb; 57():60-5. PubMed ID: 25556904
[TBL] [Abstract][Full Text] [Related]
7. Rituximab and immune deficiency: case series and review of the literature.
Kaplan B; Kopyltsova Y; Khokhar A; Lam F; Bonagura V
J Allergy Clin Immunol Pract; 2014; 2(5):594-600. PubMed ID: 25213054
[TBL] [Abstract][Full Text] [Related]
8. Rituximab Associated Hypogammaglobulinemia in Autoimmune Disease.
Tieu J; Smith RM; Gopaluni S; Kumararatne DS; McClure M; Manson A; Houghton S; Jayne DRW
Front Immunol; 2021; 12():671503. PubMed ID: 34054846
[TBL] [Abstract][Full Text] [Related]
9. Subcutaneous Immunoglobulin Therapy for Hypogammaglobulinemia Secondary to Malignancy or Related Drug Therapy.
Windegger TM; Lambooy CA; Hollis L; Morwood K; Weston H; Fung YL
Transfus Med Rev; 2017 Jan; 31(1):45-50. PubMed ID: 27450021
[TBL] [Abstract][Full Text] [Related]
10. Predicting Severe Infection and Effects of Hypogammaglobulinemia During Therapy With Rituximab in Rheumatic and Musculoskeletal Diseases.
Md Yusof MY; Vital EM; McElvenny DM; Hensor EMA; Das S; Dass S; Rawstron AC; Buch MH; Emery P; Savic S
Arthritis Rheumatol; 2019 Nov; 71(11):1812-1823. PubMed ID: 31131994
[TBL] [Abstract][Full Text] [Related]
11. Risk Factors of Pneumonia in Primary Antibody Deficiency Patients Receiving Immunoglobulin Therapy: Data from the US Immunodeficiency Network (USIDNET).
Syed MN; Kutac C; Miller JM; Marsh R; Sullivan KE; Cunningham-Rundles C; Fuleihan RL; Kheradmand F; Hajjar J
J Clin Immunol; 2022 Oct; 42(7):1545-1552. PubMed ID: 35779201
[TBL] [Abstract][Full Text] [Related]
12. Consequences of B-cell-depleting therapy: hypogammaglobulinemia and impaired B-cell reconstitution.
Sacco KA; Abraham RS
Immunotherapy; 2018 Jun; 10(8):713-728. PubMed ID: 29569510
[TBL] [Abstract][Full Text] [Related]
13. Iatrogenic antibody deficiency from B-cell targeted therapies in autoimmune rheumatic diseases.
Wijetilleka S; Jayne D; Mukhtyar C; Karim MY
Lupus Sci Med; 2019; 6(1):e000337. PubMed ID: 31413852
[TBL] [Abstract][Full Text] [Related]
14. Discontinuation of immunoglobulin replacement therapy in patients with secondary antibody deficiency.
Patel V; Cowan J
Expert Rev Clin Immunol; 2020 Jul; 16(7):711-716. PubMed ID: 32588670
[TBL] [Abstract][Full Text] [Related]
15. Profound symptomatic hypogammaglobulinemia: a rare late complication after rituximab treatment for immune thrombocytopenia. Report of 3 cases and systematic review of the literature.
Levy R; Mahévas M; Galicier L; Boutboul D; Moroch J; Loustau V; Guillaud C; Languille L; Fain O; Bierling P; Khellaf M; Michel M; Oksenhendler E; Godeau B
Autoimmun Rev; 2014 Oct; 13(10):1055-63. PubMed ID: 25183241
[TBL] [Abstract][Full Text] [Related]
16. Post-rituximab immunoglobulin M (IgM) hypogammaglobulinemia.
Kridin K; Ahmed AR
Autoimmun Rev; 2020 Mar; 19(3):102466. PubMed ID: 31917267
[TBL] [Abstract][Full Text] [Related]
17. [Prevalence of persistent hypogammaglobulinemia in patients with autoimmune rheumatic disease who received treatment with Rituximab in a national medical center in Mexico].
Fraga-Olvera A; Saavedra-Salinas MÁ; Beltrán-Mendoza JQ; Mendieta-Flores E
Rev Alerg Mex; 2023 Apr; 69(4):171-182. PubMed ID: 37218045
[TBL] [Abstract][Full Text] [Related]
18. A systematic literature review of the effects of immunoglobulin replacement therapy on the burden of secondary immunodeficiency diseases associated with hematological malignancies and stem cell transplants.
Monleón Bonet C; Waser N; Cheng K; Tzivelekis S; Edgar JDM; Sánchez-Ramón S
Expert Rev Clin Immunol; 2020 Sep; 16(9):911-921. PubMed ID: 32783541
[TBL] [Abstract][Full Text] [Related]
19. Rituximab-induced hypogammaglobulinemia and infection risk in pediatric patients.
Labrosse R; Barmettler S; Derfalvi B; Blincoe A; Cros G; Lacombe-Barrios J; Barsalou J; Yang N; Alrumayyan N; Sinclair J; Ong MS; Camargo CA; Walter J; Haddad E
J Allergy Clin Immunol; 2021 Aug; 148(2):523-532.e8. PubMed ID: 33862010
[TBL] [Abstract][Full Text] [Related]
20. Low immunoglobulin levels increase the risk of severe hypogammaglobulinemia in granulomatosis with polyangiitis patients receiving rituximab.
Besada E
BMC Musculoskelet Disord; 2016 Jan; 17():6. PubMed ID: 26738559
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
